Physician profile
Charles Rutledge
NPI 1487623971
$470.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $128.36 | 2019 | |
| Novo Nordisk INC | $60.28 | 2019 | |
| Astellas Pharma US INC | $56.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.69 | 2019 | |
| Valeritas, INC. | $36.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.59 | 2019 | |
| Glaxosmithkline, LLC. | $25.87 | 2019 | |
| Amgen INC. | $22.45 | 2019 | |
| Genentech USA, INC. | $16.26 | 2019 | |
| Lilly USA, LLC | $14.67 | 2019 | |
| Pfizer INC. | $12.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2019 | |
| Merck Sharp & Dohme LLC | $11.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rutledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.